KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 112 filers reported holding KEROS THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $527,645 | +17.9% | 16,551 | +48.5% | 0.00% | – |
| Q2 2023 | $447,685 | +0.4% | 11,142 | +6.7% | 0.00% | – |
| Q1 2023 | $445,874 | +18.6% | 10,442 | +33.4% | 0.00% | – |
| Q4 2022 | $375,853 | +24.0% | 7,827 | -2.8% | 0.00% | – |
| Q3 2022 | $303,000 | -20.1% | 8,056 | +15.4% | 0.00% | – |
| Q1 2022 | $379,000 | -6.7% | 6,980 | +0.6% | 0.00% | – |
| Q4 2021 | $406,000 | +34.9% | 6,937 | -9.0% | 0.00% | – |
| Q3 2021 | $301,000 | -90.6% | 7,627 | -89.9% | 0.00% | -100.0% |
| Q2 2021 | $3,206,000 | -72.8% | 75,504 | -60.6% | 0.00% | -66.7% |
| Q1 2021 | $11,783,000 | -12.0% | 191,423 | +0.9% | 0.00% | -25.0% |
| Q4 2020 | $13,383,000 | +84.5% | 189,719 | +0.9% | 0.00% | +100.0% |
| Q3 2020 | $7,254,000 | -35.9% | 188,082 | -37.7% | 0.00% | -50.0% |
| Q2 2020 | $11,322,000 | – | 301,825 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 276,000 | $7,626,000 | 3.44% |
| First Light Asset Management, LLC | 598,333 | $16,532,000 | 1.92% |
| Fairmount Funds Management LLC | 272,498 | $7,529,000 | 1.72% |
| Deep Track Capital, LP | 739,528 | $20,433,000 | 1.34% |
| Nantahala Capital Management | 911,901 | $25,196,000 | 1.26% |
| Octagon Capital Advisors LP | 152,249 | $4,207,000 | 1.12% |
| CHI Advisors LLC | 103,429 | $2,858,000 | 1.09% |
| Altium Capital Management LP | 88,000 | $2,431,000 | 0.97% |
| Orbimed Advisors | 1,679,417 | $46,402,000 | 0.84% |
| Parkman Healthcare Partners LLC | 47,788 | $1,320,000 | 0.49% |